康恩贝：控股股东浙药集团拟增持1.999%股份

Core Viewpoint - The controlling shareholder, Zhejiang Pharmaceutical Group, plans to increase its stake in Kang En Bei (600572.SH) by 1.999% through block trading on the Shanghai Stock Exchange, reflecting confidence in the company's growth prospects and long-term investment value [1] Group 1 - Zhejiang Pharmaceutical Group intends to acquire 50,659,020 shares, which represents 1.999% of the company's total share capital [1] - The share acquisition is expected to occur within three months after the announcement, specifically 15 trading days following the disclosure [1] - Kang En Bei Group Limited, the second-largest shareholder, will be the transferor of the shares in this block trade [1]